An Exploratory Trial of Two Dosages of a Novel Synthetic Thrombin Inhibitor (Napsagatran, Ro 46-6240) Compared with Unfractionated Heparin for Treatment of Proximal Deep-vein Thrombosis

Summary

One hundred and ten patients with acute proximal deep-vein thrombosis were randomized in a sequential dose-finding design, to receive continuous intravenous infusion of napsagatran, a novel synthetic thrombin-inhibitor, at a fixed dose of 5 mg/h (n = 37) or 9 mg/h (n = 26), or APTT-adjusted unfractionated heparin (n = 47). Oral anticoagulants were started on the 2^nd day and the study drug was discontinued from the 5^th treatment day, as soon as the International Normalized Ratio was above 2.

Control venogram (97 venogram pairs evaluable) after 5-8 days of treatment showed improvement in 3 napsagatran-treated patients (versus none in heparin-treated patients) and worsening in 4 napsagatran- treated patients (versus 2 in heparin-treated patients). The venographic Marder’s score did not change among the treatment groups. New lung scan perfusion defects (99 scintigram pairs evaluable) occurred in 4 (11%), 4 (21%), and 4 (10%) patients in the napsagatran (5 mg/h) group, in the napsagatran (9 mg/h) group, and in the heparin control group, respectively. There was no statistically significant difference in any of these endpoints between the 3 groups. No major bleeding was observed and the rare minor bleedings occurred at a similar rate in the three treatment groups.

In conclusion, the ADVENT trial has shown data that suggest comparable efficacy and safety of a synthetic, direct thrombin inhibitor (napsagatran) and conventional heparin therapy for treatment of proximal DVT. These results suggest that synthetic direct thrombin inhibitors are a promising class of antithrombotic agents which deserves further development in this field.

• References

• 1 Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-1641
• 2 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108 (Suppl.): 335S-351S
• 3 Weitz JI, Hudoba M, Massel D. et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by heparin-antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-392
• 4 Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. Chest 1995; 108 (Suppl.): 471S-485S
• 5 Tschopp TB, Ackermann J, Gast A. et al. Napsagatran, thrombin inhibitor, Ro 46-6240. Drugs of the Future 1995; 20: 476-479
• 6 Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinol 1994; 05: 879-887
• 7 Marder VJ, Soulen RL, Atichartakam V. et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
• 8 Bounameaux H, Prins TR, Schmitt HE, Schneider PA. ETTT Trial Investigators. Venography of the lower limbs: Pitfalls of the gold standard. Invest Radiol 1992; 27: 1009-1011
• 9 The PIOPED Investigators. Value of ventilation/perfusion scan in acute pulmonary embolism. JAMA 1990; 263: 2753-2759
• 2 Armitage P. Sequential medical trials. Blackwell Scientific Publications, Oxford.
• 10 Brandjes DPE, Heijboer H, Büller HR, de RijkM, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489
• 11 Parent F, Bridey F, Dreyfus M. et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70: 386-388
• 12 Ginsberg JS, Nurmohamed MT, Gent M. et al. Effects on thrombin generation of single injections of hirulog in patients with calf vein thrombosis. Thromb Haemost 1994; 72: 523-525
• 13 Moia M, Schiele F, Walker M, Erikkson H, Camez A, Lemarie JC. Treatment of acute deep vein thrombosis (DVT) with subcutaneous r-hirudin (HBW 023): a multicentre study. Thromb Haemost. 1995; 73: 1456 (abstract 2125).
• 14 Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-1574
• 15 Bounameaux H, Goldhaber SZ. Uses of low molecular weight heparin. Blood Rev 1995; 09: 213-219